CLL breakthrough: stopping treatment may be possible for some patients
NCT ID NCT04419519
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undetectable cancer cells after venetoclax treatment can stop taking the drug and stay in remission for at least a year. Researchers will monitor 81 participants to see how many remain cancer-free without ongoing therapy. The goal is to reduce unnecessary drug exposure while maintaining disease control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (with or without anti-CD20 antibody)
What this could lead to
If successful, this could show that some CLL/SLL patients can take a break from treatment without the disease coming back quickly, reducing drug side effects and costs.
What could go wrong
This is a small Phase 2 study (81 people) and results may not apply to all patients. Some patients may relapse after stopping venetoclax, and the long-term safety of treatment interruption is not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
Memorial Sloan Kettering Basking Ridge (All protocol activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (All protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All protocol activities)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, 10604, United States
-
University of Washington
Seattle, Washington, 98109, United States